EF 6265

Drug Profile

EF 6265

Latest Information Update: 04 Dec 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meiji Seika Kaisha
  • Class Antithrombotics
  • Mechanism of Action Carboxypeptidase U inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 06 Aug 2003 EF 6265 is available for licensing [www.meiji.co.jp]
  • 06 Aug 2003 Preclinical trials in Thrombosis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top